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Abstract
Background: The utility of patient screening logs and their impact on improving trial recruitment rates are unclear.
We conducted a retrospective exploratory analysis of screening data collected within a multicentre randomised
controlled trial investigating chemotherapy for upper tract urothelial carcinoma.
Methods: Participating centres maintained a record of patients meeting basic screening criteria stipulated in the
trial protocol, submitting logs regularly to the clinical trial coordinating centre (CTC). Sites recorded the number of
patients ineligible, not approached, declined and randomised. The CTC monitored proportions of eligible patients,
approach rate (proportion of eligible patients approached) and acceptance rate (proportion recruited of those
approached). Data were retrospectively analysed to identify patterns of screening activity and correlation with
recruitment.
Results: Data were collected between May 2012 and August 2016, during which time 71 sites were activated—a
recruitment period of 2768 centre months. A total of 1138 patients were reported on screening logs, with 2300
requests for logs sent by the CTC and 47% of expected logs received. A total of 758 patients were reported as
ineligible, 36 eligible patients were not approached and 207 declined trial participation. The approach rate was
91% (344/380), and the acceptance rate was 40% (137/344); these rates remained consistent throughout the data
collection. The main reason patients provided for declining (99/207, 48%) was not wanting to receive chemotherapy.
There was a moderately strong correlation (r = 0.47) between the number reported on screening logs and the number
recruited per site. Considerable variation in data between centres was observed, and 54/191 trial participants (28%)
enrolled during this period were not reported on logs.
Conclusions: Central collection of screening logs can identify reasons for patients declining trial participation and help
monitor trial activity at sites; however, obtaining complete data can be challenging. There was a correlation between
the number of patients reported on logs and recruitment; however, this was likely confounded by sites’ available
patient population. The use of screening logs may not be appropriate for all trials, and their use should be carefully
considered in relation to the associated workload. No evidence was found that central collection of screening logs
improved recruitment rates in this study, and their continued use warrants further investigation.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Rebecca.Lewis@icr.ac.uk
1Clinical Trials and Statistics Unit at the Institute of Cancer Research
(ICR-CTSU), London SM2 5NG, UK
Full list of author information is available at the end of the article
Lewis et al. Trials          (2020) 21:629 
https://doi.org/10.1186/s13063-020-04559-w
(Continued from previous page)
Trial registration: ISRCTN98387754. Registered on 31 January 2012
Keywords: Patient screening logs, Trial recruitment, Rare cancer
Background
The POUT multicentre randomised controlled trial (a
phase III randomised trial of Peri-Operative chemo-
therapy versus sUrveillance in upper Tract urothelial
cancer, CRUK/11/027) investigates the role of adju-
vant systemic chemotherapy in patients with upper
tract urothelial carcinoma (UTUC) [1]. UTUC affects
the ureter and renal pelvis and is a rare disease [2],
with an approximate annual incidence of 1–2 cases
per 100,000 people [3]. Standard treatment comprises
surgery to remove the affected kidney and ureter
(nephroureterectomy), followed by surveillance for re-
currence. Incidence of recurrence is high, with disease
returning within 5 years of the initial surgery in 30–
50% of patients with localised disease [4]. There are
few data available regarding optimal adjuvant treat-
ment strategies following surgery, and uncertainty ex-
ists regarding the value of chemotherapy, with no
international consensus [5].
The POUT trial aims to establish whether UTUC is sensi-
tive to platinum-based chemotherapy. The primary outcome
measure is disease-free survival (time from randomisation to
cancer recurrence or death), with secondary outcome mea-
sures including safety and quality of life. Following surgery,
participants were randomly allocated to either adjuvant
chemotherapy or surveillance, with treatment according to
local practice if recurrence occurred (Fig. 1). Participants
were identified by their urologist or oncologist, recruited
from secondary care hospitals across the United Kingdom
(UK), and could be approached about participation either
before or after surgery.
It is well established that recruitment to clinical trials
can be challenging, with surveys of clinical trial coordin-
ating centres (CTCs) in the UK identifying the improve-
ment of recruitment rates as a top priority [6, 7]. It was
anticipated that recruitment may be particularly difficult
in the POUT trial due to the difference between the
treatment strategies being investigated [8, 9]; the
Fig. 1 POUT trial schema
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investigators thought potential participants may be dis-
inclined to join a trial in which they could be allocated
to a group which did not receive immediate treatment,
as has been observed in other studies [10, 11]. In order
to raise awareness of the trial at an early stage in the
patient pathway, a brief pre-surgery patient information
sheet was prepared to introduce the trial to patients
prior to nephroureterectomy. This was in addition to the
main patient information sheet, given to all those
approached following surgery as part of the written in-
formed consent process. A qualitative recruitment study
was initiated to investigate recruitment activity at sites
in depth [12]. Sites were also provided with a screening
log with the intention of tracking potential participants
and helping the CTC to centrally monitor recruitment
activity at sites.
Screening logs were implemented as a result of the in-
vestigators’ prior experience, including within the SPARE
trial (a feasibility study comparing treatment modalities in
muscle-invasive bladder cancer) [13], as a tool to centrally
monitor and support recruitment activity at sites. Screen-
ing log data collected in the SPARE trial indicated that re-
cruitment to a large-scale phase III trial was not feasible
due to a lack of eligible patients and the trial therefore
closed early [8]. The use of screening logs is recom-
mended by the UK Medical Research Council’s Hubs for
Trials Methodology Research Recruitment Working
Group in their advice on optimisation of recruitment [14].
They suggest screening logs act to raise awareness of the
trial, ensure all potential recruits are reviewed, and enable
central review of eligibility criteria.
Previous studies reporting use of screening logs have
used the information gathered to justify expansion to add-
itional sites and revision of eligibility criteria, and to moni-
tor recruitment rates [15–17]. One study found that sites
submitting fewer than 50% of expected logs for two stroke
trials achieved half the monthly recruitment rate of those
submitting over 50% [18]. This was supported by similar
findings in another study which demonstrated that sites
with the highest recruitment screened the most patients
per month and recruited a higher proportion of patients
than lower-recruiting sites [19].
It has, however, been noted that there is no standard
definition of a ‘screened patient’ [19]; therefore, data can
be difficult to generalise. This represents a challenge when
trying to compare data between studies and raises ques-
tions about the validity of including screening data in ran-
domised controlled trial publications, as recommended in
the latest version of the CONSORT Statement [20]. The
recent SEAR (Screened, Eligible, Approached, Rando-
mised) publication [21] suggests a standardised framework
for collecting screening data similar to that used in the
POUT trial and, if adopted, may facilitate generalisability
between trials in the future.
The aim of this exploratory retrospective analysis is to
investigate the utility of screening logs within the POUT
trial, assess the impact of one of the changes to the trial
documentation made midway through the screening
period, investigate correlations between reported screen-
ing activity and actual recruitment and identify potential
topics for future prospective studies.
Methods
Research teams at participating NHS hospitals were pro-
vided with a screening log (Fig. 2) based on the CTC’s
standard template, and screening criteria were defined in
the trial protocol. Sites conducting surgery were asked
to record all patients receiving nephroureterectomy for
suspected UTUC. Sites to which patients were referred
following surgery were asked to record all patients fulfill-
ing the core eligibility criteria, i.e. diagnosis of locally ad-
vanced, non-metastatic UTUC. Data requested included
basic eligibility information and details of the recruit-
ment process. The aim was to capture information about
all patients fulfilling the screening criteria, with date of
surgery, histological details, dates both patient informa-
tion sheets were provided and the recruitment status (in-
eligible, not approached, declined, randomised, pending
or awaiting patient decision). If patients were happy to
disclose the reason they declined participation, this was
also recorded. Each patient was allocated a sequential
screening number, and the status was updated by the
site as required until a final outcome was reached (ineli-
gible, not approached, declined, randomised). No patient
identifiers were collected centrally; therefore, patient
consent was not required.
The log was provided to centres as a Microsoft Excel
spreadsheet, and it was recommended that it was used
as a local tool to track potentially eligible patients from
before surgery to the final outcome. Sites were asked to
submit the logs to the CTC monthly. The CTC also sent
regular reminder emails to request logs from all sites
which had been open for at least 1 month.
Upon receipt, logs were reviewed for any discrepancies
in eligibility criteria. If any patients appeared to have
been incorrectly deemed ineligible, this was raised with
the site in real time with the aim of ensuring no eligible
patients were overlooked. Sites were also regularly
reminded to report all recruited patients on the logs if
any had been omitted.
Each log received from sites was entered into a central
MS Excel spreadsheet at the CTC, and data were
cleaned to remove any patients reported in error, for
example, patients who had not had surgery or those who
did not have UTUC. Incorrect reporting of patients was
notified to sites for training purposes.
Data were summarised by the CTC and reviewed
throughout the trial with the aim of identifying any
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issues with the recruitment. Patients reported as re-
cruited, declined or not approached were classified as
eligible. Approach rate was calculated as the proportion
of those eligible who were approached (recruited + de-
clined). Acceptance rates were calculated as the propor-
tion of patients recruited of those approached. Free-text
responses were categorised according to the standar-
dised trial operating procedures.
Aggregate data were reviewed by the Trial Manage-
ment Group (TMG) which provides ongoing day-to-day
oversight of the trial, comprising the chief investigator
and key co-investigators from a cross-section of partici-
pating sites. TMG review took place every 6 months,
and screening data were used to inform revisions to the
trial documentation as deemed appropriate and to esti-
mate the impact of any such changes. Screening data
were also regularly reviewed by the qualitative recruit-
ment researcher.
In this retrospective exploratory analysis conducted by
the CTC, groups were compared using Mann-Whitney
U and, for proportions, Fisher’s exact test. Correlations
were assessed using Pearson’s correlation coefficient (r).
Data were analysed using Microsoft Excel and Stata v15.
Results
The POUT trial opened to recruitment in May 2012.
Detailed screening data were collected to August 2016.
Seventy-one recruiting sites were open, representing
2768 centre months of recruitment activity in total dur-
ing which 1138 patients were reported on screening logs
and 191 participants joined the trial (Fig. 3).
Emails requesting logs were sent in 43/50 months be-
tween June 2012 and August 2016, a total of 2300 re-
quests out of a possible 2762. The return rate following
requests was 56% (1293 logs returned in response to
2300 requests), with a total of 18 logs submitted in the
months when no request was sent (18/462 expected, 4%
return rate). Overall, 1311/2762 expected monthly logs
were received (47%). Seven centres (open for 71 centre
months in total) did not return any logs.
Of the 191 patients actually recruited to August 2016,
54 (28%), recruited at 30 sites, were not reported on
logs. Despite the ongoing CTC process of review and
data cleaning in liaison with individual sites, including
reminders to add all recruited patients to their logs,
under-reporting of participants occurred throughout the
trial with rates increasing towards the end of the screen-
ing period (Table 1).
Of the eight sites reporting no patients fitting the
screening criteria throughout the duration of the screen-
ing period, three recruited one participant each. Six of
the 25 sites which reported some screening data but no
recruited patients had actually recruited participants
(seven patients recruited across six sites).
Of the 1138 patients reported on the logs, 380 were
categorised as eligible and 344 had been approached
about participation (91% approach rate); 137 were re-
ported as joining the trial—a 40% acceptance rate (207
declining participation).
The median monthly number of approached patients
reported per centre was greater when a screening log re-
quest had been sent at the end of the month than when
no request had been sent (median, 0.138 vs 0.062 pa-
tients/centre; Mann-Whitney p = 0.04) (Table 2). How-
ever, sending a request did not increase the median
number of patients actually recruited the month after
the request was sent, when we would expect such pa-
tients to join the trial according to protocol timelines
Fig. 2 Screening log template provided to participating sites
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Fig. 3 Screening data summary
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(median, 0.062 vs 0.070 patients/centre; Mann-Whitney
p = 0.39).
A moderately strong positive correlation of 0.47 was
observed between the mean monthly number of patients
reported on screening and the mean number of partici-
pants each site actually recruited per month (Fig. 4).
Sites recruiting more than the overall median of 0.04 pa-
tients per screening month reported a median of 0.38
screened patients per month, vs 0.20 for the lower re-
cruiters (Mann Whitney p = 0.015). Higher-recruiting
sites also reported a higher acceptance rate (p < 0.0001)
(Table 3).
Sites were also categorised by whether they returned
greater than the median 47% of expected logs to the
CTC (high-returning sites) or not (low-returning sites).
Whilst numbers reported as screened and eligible per
month were greater for sites with higher numbers of
screening log returns (p = 0.001 and p = 0.04), actual
monthly recruitment was similar (p = 0.66) (Table 4.)
There was considerable variability in screening activity
per site, with no clear relationship between screening or
recruitment activity and overall acceptance rate (Fig. 5).
The pre-surgery short patient information sheet did
not appear to have any effect on acceptance rates. Of the
71 eligible patients who received the pre-surgery infor-
mation sheet, 24 joined the trial (34%), whilst the accept-
ance rate amongst the 273 patients who did not receive
a pre-surgery sheet was 41% (113/273) (p value, 0.277).
The principal reason reported for declining was not
wanting to receive chemotherapy, 99/207 (48%). Very
few patients (4/207, 2%) declined due to preference for
chemotherapy. In light of this observation, seen from the
outset of the trial and supported by findings from the
parallel qualitative study [22], the patient information
sheet was reviewed and revised in 2014, with the aim of
ensuring the information regarding the potential benefits
and drawbacks of both surveillance and chemotherapy
were outlined more clearly. From a retrospective review
of reported screening data, the revisions to the patient
information sheet made little discernible difference to
the proportion of decliners who preferred not to have
chemotherapy (48% with both versions); however, the
overall acceptance rate did marginally increase following
the implementation of the revised information sheet (38
to 42%) (Table 5).
Overall trends in recruitment rates remained relatively
stable over time (Figs. 6 and 7).
Discussion
Screening logs were a useful tool within the POUT trial as
they demonstrated that the most common reason for pa-
tients declining participation was a preference not to
undergo further treatment following surgery, contrary to
the investigators’ initial expectations that patients would
be keen to receive chemotherapy [22]. In the absence of
the qualitative recruitment study, if screening logs had not
been used, the investigators would have had a fundamen-
tal misunderstanding about why the majority of patients
declined. In addition, the investigators’ expectation that
providing information earlier in the patient pathway
would improve trial acceptance was not confirmed: there
was no indication that those patients approached prior to
surgery demonstrated higher acceptance rates than those
approached afterwards.













11 10 − 1 145 − 0.007
2013 34 40 6 590 0.010
2014 41 48 7 759 0.009
2015 40 49 9 783 0.011
2016 (January to July) 11 44 33 491 0.067
Total 137 191 54 2768 0.020

















43 2300 305 0.138 154 0.062
Screening log
request not sent
7 462 39 0.062 39 0.070
Total 50 2762 344 0.137 193 0.063
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The proportion of eligible patients declining to partici-
pate was within the wide range of decline rates reported
by other studies (15 to 80%) [15, 17, 23–26]. Whilst a
preference against chemotherapy was not anticipated by
the POUT investigators, declining due to treatment
preference is consistent with the findings of a systematic
review of participation in oncology trials [27]. Previous
studies reporting screening and recruitment data do not
provide details of the reasons for declining, instead pre-
senting aggregated data or none at all [15, 18, 23, 24,
28]. Approach rates were good throughout the trial;
however, centres may have been disinclined or unable to
report patients who were missed, so the number not
approached may have been under-reported.
We have demonstrated that screening logs were helpful
in identifying a major reason for patients declining partici-
pation in the POUT trial; however, the attempt to redress
this by amending the patient information sheet did not ap-
pear to have a major impact. Overall acceptance rates as
reported on screening logs showed little variation
throughout the trial. It is possible that prospective use of
screening data to assess the impact of changes to essential
documents or other recruitment interventions may have
been more effective than the retrospective review con-
ducted here [24].
The use of screening logs allowed near real-time cen-
tral oversight of recruitment activity at those sites which
complied with screening data reporting, enabling the
CTC to identify and feedback any misinterpretations of
eligibility criteria throughout the trial. Unfortunately,
such interventions were not systematically recorded by
the CTC; therefore, the impact of this feedback cannot
be reported.
Screening data can also be used to inform revisions to
eligibility criteria if patients in the target population are
inadvertently excluded; however, no such changes were
made within the POUT trial, despite the large propor-
tion of ineligible patients reported. We suggest any sub-
stantial alteration of criteria should be approached with
caution to avoid making the interpretation of results
challenging or risk invalidating them entirely.
Whilst the CTC not sending a request for logs did
reduce the number of patients reported for any given
month, this did not appear to impact on the number
Fig. 4 Overall recruitment rate per site vs patients reported as screened




















Low-recruiting sites (under 0.04
patients per screening month)
35 1299 0.20 0.05 0.00 0 44.7
High-recruiting sites (over 0.04
patients per screening month)
36 1469 0.38 0.14 0.08 50.0 48.0
Total 71 2768 0.26 0.10 0.03 33.3 47.1
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of patients recruited in the subsequent month, sug-
gesting that keeping and submitting screening logs
may not in itself be sufficient to improve or support
recruitment at sites.
Despite consistent requests for screening logs and
querying of submitted data, under-reporting continued to
be observed. Although this could only be confirmed by
the CTC in the discrepancy between the number of pa-
tients reported as recruited and those actually randomised,
it is likely that this under-reporting occurred across all
categories. Whilst CONSORT recommends inclusion of
screening data in clinical trial reports [20], our experience
suggests that it is challenging and time-consuming to col-
lect robust data from all participating sites, something that
we did not succeed at despite our best efforts. Hence, the
data provided to adhere to CONSORT recommendations
may not be fully representative of all screening activity.
The potential for bias should also be considered. It is feas-
ible that those sites which routinely return screening data
are unrepresentative of those which do not maintain or
submit screening logs. Whilst we observed a correlation
between the number of patients reported on screening
and those recruited, as seen by previous investigators [19],
this is likely to be confounded by the size of the patient
population available for screening (and thus recruitment)
at each site and so may not be an appropriate metric by
which to measure trial activity and engagement. No cor-
relation was observed between the proportion of expected
logs submitted to the CTC by individual sites and their re-
cruitment activity, which is inconsistent with previous
findings [18].
The resource required to obtain robust screening data
should not be underestimated. In our study, over 900 emails
requesting logs received no response. Under-reporting of
recruited patients persisted throughout the screening
period, with the lower rate at the beginning reflecting
protracted data cleaning efforts by the CTC and sites.
Maintenance and analysis of screening logs are time-
consuming, and whilst they are intended to be a beneficial
tool for sites, it may not be appropriate to implement
them for all trials. There is a debate on their utility within
the literature [18, 19], with little discussion of data quality




















35 1250 0.19 0.06 0.02 20.0 0.04
High-returning
sites (over 47%)
36 1518 0.38 0.11 0.04 37.5 0.05
Total 71 2768 0.26 0.10 0.03 33.3 0.04
Fig. 5 Screening data reported and actual recruitment per site by overall acceptance rate
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and completeness in cases where they have been used [15,
17, 24]. If a trial has a large eligible patient population and
recruitment is on target, the necessary workload may not
be beneficial, either centrally or at site. In some studies
which have reported screening data, the acceptance rate
has been extremely low—for example, a prostate cancer
trial reported 13,022 eligible men on screening, yet only
731 men were randomised [23]. This pattern has been ob-
served in other studies [18, 29]. There is a risk that the
workload associated with maintaining screening logs may
disincentivise clinicians from trial participation [27, 30],
especially if large numbers of ineligible patients have to be
reported, so screening criteria should be carefully consi-
dered if logs are used.
In the POUT trial, the anticipated eligible patient
population was small, so the workload for centres was
not anticipated to be onerous. The main time require-
ment was at the CTC, principally as a result of the rela-
tively large number of centres and the iterative process
required to obtain clean data. On reflection, given that
the approach and acceptance rates and the reasons for
declining remained relatively stable throughout data col-
lection, logs could have potentially been collected for a
shorter period.
The inconsistency in definitions and reporting of
screening data across studies makes it challenging to
generalise findings across trials. If the SEAR frame-
work, which proposes a similar data collection format
as used here, is adopted, this should help standardise
reporting of screening data [21]. It is possible that
the utility of screening data varies between disease
areas; however, standardised reporting of such data
would help elucidate this. Across all settings, the
cost-benefit ratio of collecting screening information
should be considered, as it remains unclear whether
routine use of logs substantially contributes to trial
oversight or improves recruitment rates. We intend to
investigate this further by embedding a study within
future randomised controlled trials to prospectively
investigate the utility of screening logs, the associated
resource requirements and any impact they have on
trial oversight and recruitment rates.













Reason for declining: does
not want chemotherapy
(n)
Overall decliners due to
not wanting chemotherapy
(%)
Previous version of PIS
(May 2012 to April 2014)
984 162 61 101 38 48 48
Revised PIS (May 2014
to July 2016)
1784 182 76 106 42 51 48
Total 2768 344 137 207 40 99 48
Fig. 6 Screening patterns over time
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Conclusions
Screening logs provided insight into reasons for non-
participation within the POUT trial. Data reported
remained consistent throughout the trial's duration, and
no evidence was found that central collection of screen-
ing logs improved recruitment rates. The use of screen-
ing logs may not be appropriate for all trials or for the
full duration of any given trial, and the resource require-
ments, both centrally and at site, should be carefully
considered prior to their implementation. Despite their
relatively widespread use, there exists a lack of evidence
on the utility of screening logs in supporting or improv-
ing recruitment and this warrants further investigation
within prospective studies.
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